Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Trial of the Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Patients With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST)

Trial Profile

A Phase II Trial of the Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Patients With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Jan 2019

At a glance

  • Drugs Selumetinib (Primary)
  • Indications Gastrointestinal stromal tumours
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Jan 2019 Planned initiation date changed from 11 Jan 2019 to 18 Jan 2019.
    • 05 Jan 2019 Planned initiation date (estimated date for recruitment of the first subject) changed from 4 Jan 2019 to 11 Jan 2019 .
    • 29 Dec 2018 Planned initiation date (estimated date for recruitment of the first subject) changed from 27 Dec 2018 to 4 Jan 2019 .
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top